GEN Exclusives

More »

GEN News Highlights

More »
Aug 25, 2009

BioAlliance Gets Swiss Regulatory Okay for Oral Candidasis Drug

  • BioAlliance Pharma’s share price opened today 8.5% up on the announcement that the Swiss regulatory authorities had sanctioned Loramyc®, its mucoadhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients.

    Swiss approval comes less than a week after FDA confirmed its acceptance of the NDA submission for the drug. If sanction in the U.S., Loramyc will be marketed in the country by Strativa Pharmaceuticals.

    Loramyc was first given the go-ahead in France in 2007, and roll-out in additional European countries continues. The drug made sales of €1 million, or roughly $1.43 million, in 2008. In February 2009 BioAlliance terminated its licensing agreement with SpeBio (a joint venture with SpePharm), originally signed in 2007, covering the distribution of Loramyc in EU countries excluding France. BioAlliance also initiated legal proceedings against SpeBio, citing the latter’s violation of its contractual obligations. 


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »